Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021477 | 1.00 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL7210045 | 0.92 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| Trifluoroacetic Acid SCHEMBL8108321 | 0.88 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5829872 | 0.86 | SLC6A2 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5829875 | 0.86 | SLC6A2 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL6553385 | 0.86 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5829523 | 0.86 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5830039 | 0.86 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5829782 | 0.86 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A | |
| SCHEMBL5829646 | 0.86 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | claimed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | claimed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| US-6107307-A | PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0969005-A1 | Azabicyclic inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 2000-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885SLC6A4 5/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.